Thanks to everyone who made this year’s Trans-Pacific Health Sciences Dialogue such a great success. We are grateful for the contributions of our attendees, speakers and sponsors that made this such a special event.
See you next year in Boston
Coming Soon: Gallery of Photos from the 2014 Trans-Pacific Health Sciences Dialogue
About the Conference
The Trans-Pacific Health Sciences Dialogue is a C-level meeting for biopharmaceutical industry executives who want to accelerate, explore and develop collaborations and partnerships with their counterparts in the most important Trans-Pacific health care markets including Japan, China, South Korea and North America. This is a must-attend meeting for executives who have, or want to develop, a Trans-Pacific strategy. The event has developed a well-earned reputation as the best place for biopharma companies seeking to forge Trans-Pacific ventures to start exploring their options. Attendees come away with a broad overview and insights they simply will not get in other meetings.
Who Should Attend
The Trans-Pacific Health Sciences Dialogue is an invitation-only event for Asian and North American senior biopharmaceutical executives, KOLs and select professional industry advisors, service providers and members of the financial community with a strategic interest in Trans-Pacific collaboration or investment. To request an invitation, please contact Lawrence Joseph.
Industry News from BioCentury
- PureTech raises $55MScience and technology development firm PureTech Ventures (Boston, Mass.) raised $55 million from Invesco Perpetual and other investors including endowments, angels and pharma companies. The funding builds on about $32 million in prior investments, according to CEO Daphne Zohar.
PureTech typically provides seed funding to new companies that are set up as operating subsidiaries, then seeks outside investors as the newcos mature. Zohar said the new round will allow it to provide $2-$10 million in follow-on funding to multiple programs.
Zohar said Invesco acted as a financial investor and did not receive special rights to any PureTech companies, and noted that Invesco could invest an additional $10-$50 million in any of PureTech's pipeline programs.
Among PureTech's programs are Vedanta Biosciences Inc., which is developing therapies derived from the microbiome, and Gelesis, which is developing an encapsulated device that swells in the stomach and small intestine to control appetite.
Zohar said the firm will use some of the funds to start new programs as well, and is considering projects in childhood disorders, digital medicine, population health and nutrition.
Industry News from PharmAsia
- Cipla’s Hamied Voices Continued Support For Indian Compulsory LicensesIn the last few months Cipla has made moves to co-operate with global drug makers through product licensing deals, in a clear switch in the way the Indian firm wants to do business. But outspoken chairman Yusuf Hamied, the man who demolished the patent barriers of global drug makers, continues to see reasons for India to use interventions like compulsory licenses to facilitate drug access.<img src="http://feeds.feedburner.com/~r/_PharmAsiaNews/~4/ieuehVTrt10" height="1" width="1" />
Upcoming Supporter Events
Life Science Future
October 13-14, 2014
Sheraton Downtown Hotel